

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.



Link-Asia International MedTech Group Limited

環亞國際醫療科技集團有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 1143)

(1) FURTHER DELAY IN DESPATCH OF CIRCULAR AND (2) CHANGES OF EXECUTIVE DIRECTOR

FURTHER DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcements of Link-Asia International MedTech Group Limited (the “**Company**”) dated 18 January 2022 and 9 February 2022 in relation to the Assignment of Agency Agreement involving the issue of Consideration Shares under Specific Mandate and the delay in despatch of circular (the “**Announcements**”).

As disclosed in the Announcements, a circular (the “**Circular**”) containing, among other information, (i) details of the Assignment; (ii) details of the Specific Mandate; and (iii) a notice convening the EGM together with a form of proxy for use at the EGM was expected to be despatched to the Shareholders on or before 4 March 2022. As additional time is required for the Company to finalise certain information to be included in the Circular, the Company expects that the date of despatch of the Circular will be postponed to a date falling on or before 25 March 2022.

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Link-Asia International MedTech Group Limited and together with its subsidiaries (the “**Group**”) wishes to announce that Ms. Lin Xiaoshan (“**Ms. Lin**”) has been appointed as an executive Director of the Company with effect from 4 March 2022. The biographical details of Ms. Lin are as follows:

Ms. Lin Xiaoshan

Ms. Lin, aged 32, holds a Bachelor of Communication and Information System Management* (通信與信息系統管理) from Chinese People’s Liberation Army National University of Defense Technology, School of Information Communication* (中國人民解放軍國防科技大學信息通信學院). She has over 10 years of experience in operation management and medical business management. Before joining the Group, she was a general manager of oversea projects of Shenzhen Jinjiayuan Import and Export Limited* (深圳金嘉源進出口有限公司), the managing director of Chaoshang Investment (Shenzhen) Holdings Limited* (潮商投資控股(深圳)有限公司), and executive director of Qianhai Aesthetics and Plastics Surgery Medical Group (Shenzhen) Holdings Limited* (前海醫美醫生集團(深圳)控股有限公司).

Ms. Lin will enter into a service agreement as an executive Director with the Company for an initial term of three years and will be subject to retirement by rotation and re-election at general meeting of the Company in accordance with the Company’s articles of association. Ms. Lin is entitled to an annual salary of HK\$600,000 and a discretionary bonus as specified in her service agreement, which is determined by the Board (the decision of which was based on the recommendation of the remuneration committee) with reference to her duties and responsibilities with the Company, the prevailing market rate and the remuneration policy of the Company. Such remuneration is subject to review by the remuneration committee and the Board from time to time. As a Director, Ms. Lin is subject to retirement by rotation and re-election in accordance with the articles of association of the Company.

Save as disclosed above, as at the date of this Announcement, Ms. Lin: (i) does not hold any other positions with the Company or other members of the Group; (ii) does not have any relationships with any directors, senior management or substantial or controlling shareholders (as respectively defined in the Rules Governing the Listing of Securities on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) of the Company; (iii) has not at any time during the three years preceding the date of this Announcement served nor is currently serving as a director of any other publicly listed companies in Hong Kong or overseas; and (iv) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Saved as disclosed above, there is no other information to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Listing Rules (particularly in relation to subparagraphs (h) to (v) therein) nor are there any other matters that need to be brought to the attention of the shareholders of the Company relating to the appointment of Ms. Lin.

The Board would like to take this opportunity to welcome Ms. Lin to join the Board.

RESIGNATION OF EXECUTIVE DIRECTOR

The Board also wishes to announce that Mr. Xia Xiaobing (“**Mr. Xia**”) has tendered his resignation as an executive Director of the Company with effect from 4 March 2022 to focus on his personal career development.

Mr. Xia has confirmed that he has no disagreement with the Board and that there is no matter in relation to his resignation which should be brought to the attention of the Shareholders.

The Board would like to express its sincere gratitude to Mr. Xia for his contributions to the Company during his tenure as Director of the Company.

By order of the Board
Link-Asia International MedTech Group Limited
Lin Dailian
Chairman and executive Director

Hong Kong, 4 March 2022

As at the date of this announcement, the Board comprises Mr. Lin Dailian (Chairman), Mr. Wang Guozhen, Mr. Duan Chuanhong and Ms. Lin Xiaoshan as executive Directors; Mr. Li Huiwu, Mr. Yang Weidong and Mr. Chak Chi Shing as independent non-executive Directors.

* *For identification purposes only*